BGI Genomics Hits Day Low of CNY 42.15 Amid Price Pressure

BGI Genomics Co., Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline today, with its stock price dropping by 4.66% on March 20, 2026. The stock reached an intraday low of CNY 42.15, reflecting ongoing challenges in its financial performance. Over the past week, BGI Genomics has seen a decrease of 6.1%, and its one-month performance shows a significant drop of 14.1%. The company has faced a stark decline of 29.75% over the past year, contrasting sharply with the China Shanghai Composite, which has gained 16.08% during the same period. Long-term performance indicators are also concerning, with a three-year decline of 26.64% and a staggering 63.79% drop over the last five years. Financial metrics reveal a challenging landscape for BGI Genomics, including a negative operating cash flow of CNY -119.31 million and a debt-equity ratio of -31.96%. The company has reported negative results for 16 consecutive quarters, highlighting persistent difficulties in achieving profitability. As BGI Genomics navigates these challenges, its market position remains under scrutiny.